These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8123472)

  • 1. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.
    Lee SM; Thatcher N; Crowther D; Margison GP
    Br J Cancer; 1994 Mar; 69(3):452-6. PubMed ID: 8123472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.
    Lee SM; Thatcher N; Dougal M; Margison GP
    Br J Cancer; 1993 Feb; 67(2):216-21. PubMed ID: 8431354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine.
    Lee SM; Thatcher N; Margison GP
    Cancer Res; 1991 Jan; 51(2):619-23. PubMed ID: 1824685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue.
    Lee SM; Thatcher N; Crowther D; Margison GP
    Cancer Chemother Pharmacol; 1992; 31(3):240-6. PubMed ID: 1464162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.
    Baer JC; Freeman AA; Newlands ES; Watson AJ; Rafferty JA; Margison GP
    Br J Cancer; 1993 Jun; 67(6):1299-302. PubMed ID: 8512814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
    Plummer ER; Middleton MR; Jones C; Olsen A; Hickson I; McHugh P; Margison GP; McGown G; Thorncroft M; Watson AJ; Boddy AV; Calvert AH; Harris AL; Newell DR; Curtin NJ
    Clin Cancer Res; 2005 May; 11(9):3402-9. PubMed ID: 15867241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide decreases O6-alkylguanine-DNA alkyltransferase activity in peripheral lymphocytes of patients undergoing bone marrow transplantation.
    Lee SM; Crowther D; Scarffe JH; Dougal M; Elder RH; Rafferty JA; Margison GP
    Br J Cancer; 1992 Aug; 66(2):331-6. PubMed ID: 1387001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.
    Tolcher AW; Gerson SL; Denis L; Geyer C; Hammond LA; Patnaik A; Goetz AD; Schwartz G; Edwards T; Reyderman L; Statkevich P; Cutler DL; Rowinsky EK
    Br J Cancer; 2003 Apr; 88(7):1004-11. PubMed ID: 12671695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts.
    Middleton MR; Kelly J; Goodger S; Thatcher N; Margison GP
    Cancer Chemother Pharmacol; 2000; 45(1):15-20. PubMed ID: 10647496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
    Ranson M; Middleton MR; Bridgewater J; Lee SM; Dawson M; Jowle D; Halbert G; Waller S; McGrath H; Gumbrell L; McElhinney RS; Donnelly D; McMurry TB; Margison GP
    Clin Cancer Res; 2006 Mar; 12(5):1577-84. PubMed ID: 16533784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
    Middleton MR; Lunn JM; Morris C; Rustin G; Wedge SR; Brampton MH; Lind MJ; Lee SM; Newell DR; Bleehen NM; Newlands ES; Calvert AH; Margison GP; Thatcher N
    Br J Cancer; 1998 Nov; 78(9):1199-202. PubMed ID: 9820180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.
    Wedge SR; Newlands ES
    Br J Cancer; 1996 May; 73(9):1049-52. PubMed ID: 8624262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts.
    Middleton MR; Kelly J; Thatcher N; Donnelly DJ; McElhinney RS; McMurry TB; McCormick JE; Margison GP
    Int J Cancer; 2000 Jan; 85(2):248-52. PubMed ID: 10629085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
    Middleton MR; Thatcher N; McMurry TB; McElhinney RS; Donnelly DJ; Margison GP
    Int J Cancer; 2002 Aug; 100(5):615-7. PubMed ID: 12124813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships among cell survival, O6-alkylguanine-DNA alkyltransferase activity, and reactivation of methylated adenovirus 5 and herpes simplex virus type 1 in human melanoma cell lines.
    Maynard K; Parsons PG; Cerny T; Margison GP
    Cancer Res; 1989 Sep; 49(17):4813-7. PubMed ID: 2547518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between the formation of O6-methyldeoxyguanosine by 1-p-carboxyl-3,3-dimethylphenyltriazene in DNA and O6-alkylguanine-DNA alkyltransferase in human peripheral leukocytes.
    Lee SM; O'Connor PJ; Thatcher N; Crowther D; Margison GP; Cooper DP
    Cancer Res; 1994 Aug; 54(15):4072-6. PubMed ID: 8033139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study.
    Middleton MR; Lee SM; Arance A; Wood M; Thatcher N; Margison GP
    Int J Cancer; 2000 Nov; 88(3):469-73. PubMed ID: 11054678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.
    Spiro TP; Liu L; Majka S; Haaga J; Willson JK; Gerson SL
    Clin Cancer Res; 2001 Aug; 7(8):2309-17. PubMed ID: 11489806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
    Gander M; Leyvraz S; Decosterd L; Bonfanti M; Marzolini C; Shen F; Liénard D; Perey L; Colella G; Biollaz J; Lejeune F; Yarosh D; Belanich M; D'Incalci M
    Ann Oncol; 1999 Jul; 10(7):831-8. PubMed ID: 10470431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy.
    Lee SM; Margison GP; Thatcher N; O'Connor PJ; Cooper DP
    Br J Cancer; 1994 May; 69(5):853-7. PubMed ID: 8180013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.